Fresenius announced the acquisition of Akorn, a US-based manufacturer and marketer of prescription and over-the-counter pharmaceuticals, for an EV of US$4.8bn. Closing is expected to be in H1 18. Additionally, the company is taking over the biosimilar portfolio of Merck KGaA for €170m upfront and up to €500m in milestone payments. Both acquisitions will be fully debt- and cash-flow financed.
25 Apr 2017
Drumbeats at Kabi
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Drumbeats at Kabi
Fresenius SE & Co. KGaA (FRE:WBO) | 0 0 0.5% | Mkt Cap: 35,173m
- Published:
25 Apr 2017 -
Author:
Martin Schnee -
Pages:
3
Fresenius announced the acquisition of Akorn, a US-based manufacturer and marketer of prescription and over-the-counter pharmaceuticals, for an EV of US$4.8bn. Closing is expected to be in H1 18. Additionally, the company is taking over the biosimilar portfolio of Merck KGaA for €170m upfront and up to €500m in milestone payments. Both acquisitions will be fully debt- and cash-flow financed.